Bioventus Inc. (NYSE:BVS) Shares Acquired by Prudential Financial Inc.

Prudential Financial Inc. grew its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 650.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,260 shares of the company's stock after purchasing an additional 76,500 shares during the quarter. Prudential Financial Inc. owned about 0.11% of Bioventus worth $927,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in Bioventus by 38.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company's stock worth $4,662,000 after buying an additional 109,359 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Bioventus during the 3rd quarter valued at about $788,000. JPMorgan Chase & Co. grew its holdings in shares of Bioventus by 228.3% in the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock valued at $3,032,000 after purchasing an additional 176,442 shares during the period. State Street Corp increased its position in Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company's stock worth $8,084,000 after purchasing an additional 189,216 shares during the last quarter. Finally, Barclays PLC raised its stake in Bioventus by 24.2% during the third quarter. Barclays PLC now owns 50,654 shares of the company's stock worth $606,000 after purchasing an additional 9,854 shares during the period. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Bioventus Trading Down 1.2 %

Shares of BVS traded down $0.09 during trading on Friday, reaching $7.48. 306,469 shares of the company traded hands, compared to its average volume of 440,895. The stock has a 50-day simple moving average of $9.59 and a 200-day simple moving average of $10.73. The stock has a market cap of $612.94 million, a PE ratio of -12.26 and a beta of 0.92. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85.

Insider Buying and Selling

In other Bioventus news, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares of the company's stock, valued at $1,204,233.82. The trade was a 3.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Robert E. Claypoole sold 28,786 shares of the business's stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now owns 64,964 shares in the company, valued at $591,172.40. This trade represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 46,161 shares of company stock valued at $436,364. Company insiders own 32.90% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on BVS shares. JPMorgan Chase & Co. raised shares of Bioventus from an "underweight" rating to a "neutral" rating and increased their price target for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price objective on shares of Bioventus in a research report on Monday, March 17th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.